AVANIR Pharmaceuticals, Inc., a biopharmaceutical company focused on acquiring, developing, and commercializing novel therapeutic products for the treatment of central nervous system disorders, recently announced that the company has received a “Notice of Allowance” from the United States Patent and Trademark Office (USPTO) for its lead drug candidate Zenvia™, a treatment pseudobulbar affect (PBA).

This patent will provide AVANIR Pharmaceuticals commercial exclusivity for PBA indication well into 2025. AVANIR Pharmaceuticals also has exclusive rights to other patents and patent applications for treating PBA, chronic pain and other neurologic conditions using combinations of dextromethorphan and quinidine.

Greg Flesher, vice president of business development at AVANIR Pharmaceuticals, stated, “We are very pleased with the decision by the USPTO to grant this patent for our low-dose quinidine formulations of Zenvia for treating pseudobulbar affect. The new Zenvia patent will strengthen our worldwide intellectual property portfolio and is expected to provide fifteen years of commercial exclusivity

Muscle Flex Inc. announced that it has submitted its trademark application for The Beagle StepFit with the USPTO (United States Patent and Trademark Office). The Beagle StepFit is a multi-functional pedometer that clips onto the waist of an individual for walking or running and provides the wearer with detailed information as to how many steps the person has taken as well as the distance traveled. In addition to these standard features, however, Muscle Flex has taken the pedometer one step further by including the following features:

1. Body Fat Monitor 2. Step Counter 3. Calorie Burn Counter 4. Distance Calculator 5. Exercise timer 6. Clock with Alarm: 12/24 Hour format

According to the press release, Muscle Flex is working on a 1 and 2 minute short form direct response commercial for the Beagle that will be aired

PennyOmega.com Stock Report!

PennyOmega.com Hot Stock News & Alerts!

Tuesday August 18, 2009

PennyOmega.com Stock Report!

**************************************************************

Lazard Ltd (NYSE:LAZ) announced today that Tom Tuft, one of the leading bankers in equity capital markets, will join Lazard as Chairman, Global Capital Markets Advisory, and a Vice Chairman, US Investment Banking in November. Mr. Tuft, based in New York, will join Lazard from Goldman Sachs & Co., where he most recently served as Chairman of its Equity Capital Markets group.

UDR, Inc. (NYSE: UDR), a leading multifamily real estate investment trust (REIT), today announced that it has extended the early tender deadline in respect of its previously announced cash tender offer and consent solicitation (the “Offer”) for its

WABCO Holdings Inc. (NYSE: WBC) (www.wabco-auto.com), a global technology leader and tier-one supplier to the commercial vehicle industry, today announced that WABCO and Ashok Leyland, the Indian flagship of the Hinduja Group, have completed an agreement for development of transmission automation technology and the long term supply of automated manual transmission (AMT) systems from 2010 through 2015.

Millicom International Cellular S.A. (”Millicom”) (NASDAQ:MICC) (STO:MIC) today announces that it has signed an agreement for the sale of its Cambodian operations to The Royal Group, its partner in Cambodia, for $346m in cash, payable on completion. This transaction comprises Millicom’s 58.4% holdings in CamGSM, Royal Telecam International and Cambodia Broadcasting Services.

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, and Regulus Therapeutics Inc., a leading microRNA therapeutics company, announced today that the United States Patent and Trademark Office (USPTO) has awarded a notice of allowance for the Manoharan patent (application number

Access Pharmaceuticals, Inc.

(OTC:ACCP)

Many investors have raised concerns with regards to Access Pharmaceuticals being on the OTC. Indeed more than half the time companies which are not listed on a major exchange tend to lie, cheat and do just about anything possible in order to stimulate investor demand. They will reach out to stock promoters, make deals with various PR companies and even go as far as releasing their own false press releases — usually involving buyouts (see OTC:PGYC). Folks, you need not worry, Access Pharma takes part in none of these illegal activities in order to induce demand, rather they focus on a solid and sound business strategy which willslowly take them into the promise land. Patience is a virtue.

MuGard is an interesting product with a lot of potential, and we truly believe that it

Since I last wrote about Access Pharma [ACCP: 0.00, N/A (N/A)] two weeks ago as a cancer biotech call option trade, the Company has issued two updates on its clinical development pipeline and two updates for MuGard – which is an oral rinse product for the management of a common side effect of many cancer therapies, mucositis. In late May, Access announced that MuGard was launched in Germany, Italy, UK, Greece, and the Nordic countries by its European commercial partner, SpePharm, with expected launches in North America, Asia, and other regions slated for later this year. On 6/10/09, ACCP.OB also announced that the Company received issue notifications from the United States Patent and Trademark Office for two US patents (numbers 7,544,348 and 7,547,433).

A video presentation is available at ProActiveNewsRoom.com for MuGard, in addition to more information and links at the landing page

Access Pharmaceuticals Inc., an emerging biopharmaceutical company, is focused on developing novel nanopolymer delivery technologies and products for cancer and dermatology. Currently, the company has one approved product, one product in phase 3 clinical development, four products in phase 2, and six products in preclinical development.

Although Access’ primary focus is on oncology and supportive care of cancer patients, the company has acquired product candidates in the dermatology field as well as additional oncology assets. The business development team is interested in identifying out-licensing candidates, as well as alliance and merger opportunities for the company’s oncology and dermatology products, as well as nanopolymer technologies.

In most recent news, Access announced that it has received issue notifications from the United States Patent and Trademark Office that two US patents relating to MuGard TM , the company’s approved oral rinse product for the management of mucositis, will issue this month. MuGard is a ready-to-use

Next-generation alternative and renewable energy developer New Energy Technologies, Inc. announced that it has filed nine new patent applications with the United States Patent and Trademark Office (USPTO) in order protect novel features of its recently prototyped MotionPower™ technology.

According to the U.S. Energy Information Administration, coal and natural gas generate 70% of the United State’s electricity. The environmental impact of greenhouse gas emissions, rising costs of non-renewable fuels, and the potential doubling of global electricity consumption in the coming years illustrates the need for creative, sustainable methods for generating electricity in the United States. In response, New Energy engineers developed MotionPower™ technologies to generate ‘clean’ electricity by harnessing the kinetic energy of the estimated 250 million registered vehicles operating on America’s roads every day.

Mr. Meetesh V. Patel, President and CEO of New Energy Technologies, Inc. stated, “In recent weeks, our engineers have achieved a major development milestone by completing

Both existing and potential investors of Kraig Biocraft Laboratories Inc (KBLB.OB) should understand that they have one of the most pioneering and accomplished minds in the field of genetic engineering working in their corner. This member of Kraig’s Scientific Advisory Board, Dr. Malcolm Fraser, presides over the University of Notre Dame’s transgenic-based laboratory which has currently been focusing on developing “spider silk” polymers.

Since Kraig and Notre Dame have partnered in a collaboration agreement, essentially exchanging funding for both R&D data and intellectual property rights, Kraig is uniquely positioned to benefit from the work conducted under Dr. Fraser at Notre Dame. Consequently, the company’s stock performance will be heavily tied to Dr. Fraser’s breakthroughs in the laboratory.

Considering Kraig’s track record, investors should feel at ease with the notion that his work can single handedly affect Kraig’s stock price. Shortly after the

The Children’s Internet Inc. dedicates their efforts to creating an Internet environment that fully realizes the promise and educational potential of the Web. They work to do this with the reassurance and safety that parents demand for their children. Trading on the OTCBB, the company has their headquarters in Gold River, California. Their portal is at www.thechildrensinternetinc.com. The Company is the exclusive marketer and distributor of The Children’s Internet® membership based service created just for kids.

The Children’s Internet Inc. developed their vision of a “Kid-Wide Web”. It balances protection, education, and fun. Children can explore the Internet safely, free of the dangers typically associated with unsupervised access. Their portal is a comprehensive, secure Internet service and “educational super portal” for children. It serves pre-school to junior high students. Children have real time access to millions of the best pre-selected, pre-approved educational and entertaining web pages. They can access